ASCO 2025: Introduction of Neoantigen-Specific Immune Responses by VB10.NEO in Combination with Atezolizumab in Heavily Pretreated Patients with Advanced Solid Tumors: Final Analysis of the Phase 1b VB-N-02 Trial